Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.54 |
| ▸ | FAAH | O00519 | 7/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799313 | 0.89 | HDAC3 (0.40) | MGLLFAAHPLA2G4BTSHRRECQL | |
| SCHEMBL13799303 | 0.87 | TSHR (0.65) | PLA2G4BTSHRRECQLRARB | |
| SCHEMBL13799312 | 0.86 | MGLL (0.39) | MGLLFAAHPLA2G4BTSHRRECQL | |
| SCHEMBL21902733 | 0.83 | MGLL (0.57) | MGLLFAAHTSHRRECQL | |
| SCHEMBL13812779 | 0.81 | PLA2G4B (0.67) | PLA2G4BTSHRRARB | |
| SCHEMBL21902727 | 0.78 | MGLL (0.64) | MGLL | |
| SCHEMBL27134652 | 0.78 | MGLL (0.58) | MGLLFAAH | |
| SCHEMBL14097166 | 0.76 | RARB (0.57) | FAAHPLA2G4BTSHRRARB | |
| SCHEMBL4159198 | 0.76 | TSHR (0.52) | PLA2G4BTSHRRECQL | |
| SCHEMBL13382749 | 0.75 | LMNA (0.68) | PLA2G4BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796267-B2 | Oxazolidinone derivatives and methods of use | CONCERT PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20090163380-A1 | ANALYTE FOCUSING BIOCHIPS FOR AFFINITY MASS SPECTROMETRY | STRATOS BIOSYSTEMS, LLC (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163380-A1 | ANALYTE FOCUSING BIOCHIPS FOR AFFINITY MASS SPECTROMETRY | STUB1, SPR, DBI | MGLL 3919/4885FAAH 2160/4885PLA2G4B 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.